Compare SHOO & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | LGND |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 1996 | 1997 |
| Metric | SHOO | LGND |
|---|---|---|
| Price | $45.06 | $302.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $42.14 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 979.1K | 164.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | 1.38 | ★ 1.63 |
| Revenue | ★ $2,534,109,000.00 | $141,102,000.00 |
| Revenue This Year | $12.39 | $1.25 |
| Revenue Next Year | $5.90 | $19.41 |
| P/E Ratio | ★ $32.05 | $183.46 |
| Revenue Growth | 11.00 | ★ 29.48 |
| 52 Week Low | $31.33 | $166.10 |
| 52 Week High | $49.70 | $326.63 |
| Indicator | SHOO | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 65.55 |
| Support Level | $41.44 | $286.99 |
| Resistance Level | $46.85 | $317.49 |
| Average True Range (ATR) | 1.37 | 8.66 |
| MACD | 0.37 | 2.57 |
| Stochastic Oscillator | 93.67 | 99.79 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.